Warning! GuruFocus detected
3 Severe warning signs
with MAB.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Mabion SA
NAICS : 325412
SIC : 2833
ISIN : PLMBION00016
Description
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.6 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.12 | |||||
| Interest Coverage | 9.77 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.88 | |||||
| Beneish M-Score | -4.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year FCF Growth Rate | 3.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.32 | |||||
| 9-Day RSI | 22.2 | |||||
| 14-Day RSI | 28.87 | |||||
| 3-1 Month Momentum % | 2.2 | |||||
| 6-1 Month Momentum % | -36.91 | |||||
| 12-1 Month Momentum % | -38.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.45 | |||||
| Quick Ratio | 1.26 | |||||
| Cash Ratio | 1.15 | |||||
| Days Inventory | 112.41 | |||||
| Days Sales Outstanding | 50.93 | |||||
| Days Payable | 72.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | 0.89 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 78.29 | |||||
| Operating Margin % | 28.73 | |||||
| Net Margin % | 9.24 | |||||
| FCF Margin % | 13.79 | |||||
| ROE % | 7.91 | |||||
| ROA % | 4.98 | |||||
| ROIC % | 10.38 | |||||
| 3-Year ROIIC % | 916.08 | |||||
| ROC (Joel Greenblatt) % | 18.52 | |||||
| ROCE % | 14.35 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.97 | |||||
| PE Ratio without NRI | 6.88 | |||||
| Price-to-Owner-Earnings | 9.97 | |||||
| PS Ratio | 1.34 | |||||
| PB Ratio | 1.14 | |||||
| Price-to-Tangible-Book | 1.14 | |||||
| Price-to-Free-Cash-Flow | 9.88 | |||||
| Price-to-Operating-Cash-Flow | 3.19 | |||||
| EV-to-EBIT | 4.71 | |||||
| EV-to-EBITDA | 3.44 | |||||
| EV-to-Revenue | 0.94 | |||||
| EV-to-FCF | 6.82 | |||||
| Price-to-GF-Value | 0.68 | |||||
| Price-to-Graham-Number | 0.59 | |||||
| Price-to-Net-Current-Asset-Value | 16.02 | |||||
| Earnings Yield (Greenblatt) % | 21.23 | |||||
| FCF Yield % | 10.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Mabion SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil zł) | 110.793 | ||
| EPS (TTM) (zł) | 0.61 | ||
| Beta | 2.4 | ||
| 3-Year Sharpe Ratio | -0.58 | ||
| 3-Year Sortino Ratio | -0.83 | ||
| Volatility % | 40.16 | ||
| 14-Day RSI | 28.87 | ||
| 14-Day ATR (zł) | 0.374577 | ||
| 20-Day SMA (zł) | 9.845 | ||
| 12-1 Month Momentum % | -38.73 | ||
| 52-Week Range (zł) | 8.38 - 20.45 | ||
| Shares Outstanding (Mil) | 16.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mabion SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mabion SA Stock Events
| Event | Date | Price (zł) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mabion SA Frequently Asked Questions
What is Mabion SA(WAR:MAB)'s stock price today?
The current price of WAR:MAB is zł9.13. The 52 week high of WAR:MAB is zł20.45 and 52 week low is zł8.38.
When is next earnings date of Mabion SA(WAR:MAB)?
The next earnings date of Mabion SA(WAR:MAB) is .
Does Mabion SA(WAR:MAB) pay dividends? If so, how much?
Mabion SA(WAR:MAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers